Antibiotics, Vitamin K, and the Gut Microbiome: When It Actually Matters

Vitamin K exists in two main forms: vitamin K1 (phylloquinone), which comes mainly from leafy green vegetables, and the vitamin K2 group (menaquinones), which come partly from food (e.g. natto or certain cheeses) and partly from synthesis by bacteria living in the colon. A substantial portion of the menaquinones used in the human body is estimated to come from this bacterial synthesis in the gut — though the exact share it contributes to total vitamin K requirements is still being studied and likely varies between individuals depending on their microbiome composition.

Gut bacteria that produce menaquinones include certain strains of Escherichia coli, Bacteroides fragilis, Eggerthella lenta, and Lactococcus lactis — different bacterial groups synthesize different menaquinone subtypes (from MK-5 to MK-13), meaning a change in microbiome composition (dysbiosis) can affect not just the total amount of vitamin K synthesized, but the profile of its specific forms too.

Broad-spectrum antibiotics — ones that kill many different groups of bacteria, not just the specific pathogen causing an infection — can therefore theoretically lower this internal, bacterial synthesis of vitamin K along with destroying the bacteria that produce it. That's an intuitively obvious mechanism, but as clinical practice shows, its greatest significance isn't in healthy people without additional risk factors, but in a very specific group of patients, which we return to later in this article.

The mechanism of this interaction is complex and probably isn't limited solely to the effect on the microbiome — some antibiotics (e.g. certain macrolides, metronidazole, co-trimoxazole) also inhibit liver enzymes that metabolize warfarin, which independently strengthens its effect regardless of any impact on vitamin K. Still, reduced menaquinone synthesis by a disrupted microbiome is recognized as one significant, well-described mechanism of this interaction, especially with longer courses of broad-spectrum antibiotic therapy.

Clinical practice shows that INR changes after starting an antibiotic in a patient on warfarin most often appear between days 3 and 10 of therapy, with the largest changes typically observed between days 3 and 7 — matching the time needed to deplete existing vitamin K stores and slow new synthesis by a damaged microbiome. Some analyses suggest that as many as 12–16% of warfarin patients on antibiotic therapy develop a supratherapeutic INR.

In the literature on antibiotic-warfarin interactions, ceftriaxone — a broad-spectrum cephalosporin — is particularly often mentioned, having been linked in several studies to a statistically greater INR rise than other antibiotics used for similar indications (e.g. treating urinary tract infections). Metronidazole, co-trimoxazole (trimethoprim-sulfamethoxazole), and certain fluoroquinolones (levofloxacin, gatifloxacin) are also frequently mentioned — several of these drugs work through an additional mechanism of inhibiting warfarin metabolism in the liver, independent of their effect on the microbiome, which makes them particularly strong "amplifiers" of the anticoagulant effect.

A mechanistic study in cardiac surgery patients confirmed the microbiome's role in this relationship directly, not just through clinical correlation with antibiotic use.

In people not taking anticoagulants, an overt, clinically apparent vitamin K deficiency caused by antibiotics alone is rare, but not impossible — the literature describes isolated cases of coagulopathy (clotting disorders) linked to vitamin K deficiency in patients after prolonged, intensive broad-spectrum antibiotic therapy, usually in hospital settings, often combined with limited oral food intake (and thus limited dietary vitamin K) and additional risk factors such as liver disease.

A particular, well-described case is pseudomembranous colitis caused by Clostridioides difficile, which can develop after antibiotic therapy and, through severe disruption of the gut microbiome and sometimes coexisting absorption problems, can itself lead to a vitamin K deficiency significant enough to raise INR even in patients not on warfarin. This, though, is a scenario involving serious illness, not a typical, short course of antibiotics prescribed in an outpatient setting.

An intuitive solution seems to be taking probiotics during or after antibiotic therapy to more quickly rebuild the destroyed microbiome, including the bacteria that synthesize vitamin K. The evidence on this, though, is more complex and less clearly positive than intuition would suggest — worth saying plainly rather than presenting probiotics as a ready-made solution.

This doesn't mean probiotics are harmful or have no use in the context of antibiotic therapy — other studies and meta-analyses point to benefits of probiotics in preventing antibiotic-associated diarrhea, which is a separate endpoint from the speed and completeness of full microbiome recovery. The conclusion from the Suez et al. study is narrower and more specific: if the goal is the fastest possible return of a native, diverse microbiome (including vitamin K-synthesizing bacteria) to its pre-antibiotic state, routine, universal use of standard multi-strain probiotics isn't as helpful as commonly assumed — and in this particular study was actually counterproductive.

The practical conclusion is therefore measured: evidence on probiotics in the context of post-antibiotic microbiome recovery is mixed and depends on exactly which effect is being assessed (antibiotic-associated diarrhea versus full recovery of microbiome diversity). For patients on warfarin, the most important practical step remains not self-directed probiotic supplementation, but reporting every new antibiotic to the doctor managing anticoagulant therapy and more frequent INR monitoring during that period.

This topic is a good example of how important it is to precisely define who a given biological mechanism actually matters for clinically. The fact that antibiotics weaken bacterial vitamin K synthesis is true and well documented mechanistically — but its practical consequences concern primarily a narrow, specific group of patients on warfarin, not the general population taking an antibiotic for an ordinary infection. The biggest mistake would be either ignoring this topic in patients on anticoagulants, or needlessly worrying about it in people it doesn't practically apply to.